Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OncoStrong
- Development stage
- Preclinical
- Lead developer
- Lamark
- Administration
- Inhalation
01
Overview
OncoStrong is a preclinical-stage inhaled powder biologic developed by Lamark Biotech for the treatment of lung cancer. The therapeutic utilizes Lamark's proprietary Proteostrong™ technology, which is designed to produce thermostable, dry-powder formulations of biologics. This platform enables direct delivery to the respiratory tract via inhalation, potentially increasing the local concentration of the drug in lung tissue while reducing systemic exposure and side effects. While the specific molecular target of OncoStrong has not been publicly disclosed, the Proteostrong platform is intended to be applicable to various biologic modalities and multiple cancer types beyond lung cancer.
- Brand names
- OncoStrong
Beyond the preview
Go deeper on OncoStrong.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoStrong.